Short answer
MeiraGTx Holdings plc (MGTX) filed an 8-K current report with the SEC on April 24, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Strategic collaboration completed April 20, 2026, covering Parkinson’s, genetic obesity, CNS gene therapies, and delivery-device commercialization.
MeiraGTx Holdings plc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Strategic collaboration completed April 20, 2026, covering Parkinson’s, genetic obesity, CNS gene therapies, and delivery-device commercialization
- Hologen’s $105 million prior payments count toward a $200 million upfront commitment
- Hologen to own 70% of Hologen Neuro AI; MeiraGTx retains 30% after remaining upfront funding
- Hologen receives manufacturing ownership, potentially reaching 40% through an option expiring 12 months after exercise availability
- MeiraGTx may repurchase Hologen’s manufacturing stake beginning year three through year six at Hologen’s purchase price
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MeiraGTx Holdings plc 8-K filings
Get the next MGTX 8-K as it lands
Follow MGTX for push alerts, or ask the research agent what this filing means.